### **Overview** Chemcon Speciality Chemicals Ltd, established in 1988 (originally incorporated as Gujarat Quinone Private Limited), is a leading Indian manufacturer of specialty chemicals with a strong focus on **pharmaceutical intermediates** and **inorganic bromides** used in oilfield completion fluids. The company operates from an integrated manufacturing complex in **Manjusar, Vadodara, Gujarat**, and serves a growing global clientele across over 15 countries, including the USA, Germany, China, Japan, South Korea, and Russia. Key products include: - **Hexamethyl Disilazane (HMDS)** – a critical silylating agent in pharmaceuticals and high-purity applications in semiconductors and rubber. - **Chloromethyl Isopropyl Carbonate (CMIC)** – a key intermediate in antiviral drugs such as Tenofovir (used for HIV and Hepatitis B). - **Inorganic Bromides** – including Calcium Bromide, Zinc Bromide, and Sodium Bromide, used as high-density completion fluids in oil & gas exploration. - **Bromobenzene and other organic chemicals** – serving agrochemical manufacturers globally. --- ### **Market Position & Competitive Advantage** - **HMDS**: - The **only Indian manufacturer**. - **Third-largest global producer**. - Domestic demand exceeds supply, with India importing ~40% of its HMDS needs, creating a strong **import substitution** opportunity. - **CMIC**: - **World’s largest manufacturer** by volume. - Holds **~30% global market share**. - India imports ~62% of its CMIC consumption, further underscoring domestic demand potential. - **Bromides**: - **Sole Indian producer** of **Zinc Bromide**. - **Largest producer** of **Calcium Bromide** in India. - Holds ~3% global production capacity in bromides. The company benefits from **cost leadership** stemming from its single-location manufacturing cluster, dedicated plants per product, process re-engineering, and economies of scale. --- ### **Strategic Developments (Nov 2025)** 1. **Acquisition of Shivam Petrochem Industries**: - Completed via **slump sale** for **₹36 crore**. - Adds **pharmaceutical intermediates** such as Trityl Chloride (TTC), 2-Chlorotrityl Chloride (2CTC), TosMIC, PTSCL, and several **thiophene/pyridine derivatives**. - Strategic rationale: - Expands core product portfolio. - Enables **cost and operational synergies**. - Gains **technical capabilities** and **new customer access**. - Strengthens position in bulk drugs, chemical intermediates, and solvents. 2. **Production & Capacity Expansion**: - Ongoing development of **P10 and P11 manufacturing units** at Manjusar. - Units will produce **high-value organic chemicals**, especially those currently **imported** into India. - Targeted to **de-risk the portfolio**, reduce import dependency, and diversify into non-pharma sectors (e.g., rubber, semiconductors). - Expected to be commissioned in **H1 FY26**. 3. **Diversification & Innovation**: - Expanding applications of **HMDS** into **rubber and semiconductor industries**. - Investing in **R&D and process engineering** to improve synthesis efficiency, reduce solvent usage, and shorten cycle times. - Focus on commercializing **new products** with niche applications and high entry barriers. --- ### **Customer Base & Market Reach** - **Top 5 customers** contribute ~30–40% of revenue; **top 10** account for ~45–58%, indicating **moderate customer concentration**. - Long-standing relationships with **major clients** (e.g., **Shree Radha Overseas**, **CC Gran Limited Liability Company**) exceeding **20 years**, supporting market stability and customer retention. - Exports form a significant portion of revenue (~29% in FY21), with a growing footprint in **Europe, East Asia, and North America**. - ISO 9001:2015 and ISO 14001:2015 certified for **pharmaceutical intermediates, silanes, and oilfield chemicals**, ensuring compliance with global quality and environmental standards. --- ### **Facilities & Infrastructure** - **Nine operational manufacturing plants** in **Manjusar, Gujarat**. - **Two additional plants (P10 & P11)** under development. - **Total installed capacity**: - **10,800 MTPA** for organic chemicals (including CMIC, HMDS, Bromobenzene). - **15,000 MTPA** for inorganic bromides. - **In-house R&D laboratory** for product development and **quality control**. - **Seven warehouses**: 6 owned and 1 leased. - **Marketing offices** in **Mohali and Hyderabad**. - **Backward integration** achieved through **TMCS production (2,400 MTPA)** at P8, a key raw material for HMDS, reducing reliance on imports. - **Solar power plant** (2.1 MW) operational at Dabhoi, reducing captive power costs and carbon footprint. --- ### **Growth Strategy** - **Import Substitution**: - A core focus given India’s heavy reliance on imported HMDS, CMIC, and other specialty chemicals. - Government initiatives like **Atmanirbhar Bharat** and **PLI schemes** are expected to further boost domestic chemical manufacturing. - **Export Growth**: - Strengthening international distribution to reduce dependence on domestic market volatility. - **Product & Market Diversification**: - Expanding into agrochemicals (via Bromobenzene), semiconductors (high-purity HMDS), and niche pharma intermediates (e.g., Guanine, 2,5-DHT, 4-CBC). - **Sustainability & Efficiency**: - Zero-liquid discharge (ZLD) compliance. - Continuous investment in process optimization and energy efficiency. --- ### **Financial & Operational Highlights** - Strong customer retention with **long-term contracts** and **multi-year relationships**. - **13% YoY volume growth** reported in early 2024, driven by inorganic chemicals and new organic product launches. - Investments in P10/P11 and recent acquisition (₹36 crore) funded through **internal accruals and strategic capital planning**. - Recent revenue contributions (past disclosures): - **CMIC**: ~25–36% of revenue. - **HMDS**: ~50% of revenue (primarily domestic). - **Bromides**: ~30–38% of revenue (increasing international share).